Fresenius Medical Care AG Share Buyback Program Launch

Fresenius Medical Care AG ("FME") announced the commencement of its share buyback program on May 28, 2026, with the first tranche valued at up to EUR 600 million, expected to conclude by December 15, 2026. The overall program, authorized by the General Meeting on May 21, 2026, has a total value of up to EUR 1 billion and is scheduled to be completed within 12 months by May 27, 2027. The repurchased shares are primarily intended for cancellation to reduce share capital, with a smaller portion possibly allocated to employee incentive plans. This initiative is part of FME's capital allocation strategy, balancing dividends with disciplined capital management. The buyback adheres to regulatory guidelines, including Regulation (EU) No 596/2014 and Delegated Regulation (EU) 2016/1052, with a credit institution managing the buyback independently. FME will disclose transaction details and provide regular updates on the program's progress via its investor relations website.